Phase I dose-escalation study of the safety, tolerability, and pharmacokinetics of aflibercept in combination with S-1 in Japanese patients with advanced solid malignancies

Background Aflibercept, a recombinant fusion protein binding VEGF-A, VEGF-B and placental growth factor, inhibits tumor growth by blocking angiogenesis. The aim of this phase I dose-escalation study was to determine the recommended phase II dose (RP2D) of aflibercept in combination with S-1 in Japan...

Descripción completa

Detalles Bibliográficos
Autores principales: Doi, Toshihiko, Boku, Narikazu, Onozawa, Yusuke, Takahashi, Keishiro, Kawaguchi, Osamu, Ohtsu, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497698/
https://www.ncbi.nlm.nih.gov/pubmed/31907738
http://dx.doi.org/10.1007/s10637-019-00888-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497698/
https://www.ncbi.nlm.nih.gov/pubmed/31907738
http://dx.doi.org/10.1007/s10637-019-00888-z

Ejemplares similares